pioglitazone has been researched along with Graves Ophthalmopathy in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Graves Ophthalmopathy: An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 7.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
| "Until now, the following are not known: (1) the mechanisms underlying the induction of chemokine (C-X-C motif) ligand 10 (CXCL10) secretion by cytokines in thyrocytes; (2) if pioglitazone is able, like rosiglitazone, to inhibit the interferon (IFN)-γ-induced chemokine expression in Graves disease (GD) or ophthalmopathy (GO); and (3) the mechanisms underlying the inhibition by thiazolidinediones of the cytokines-induced CXCL10 release in thyrocytes." | 3.77 | Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. ( Antonelli, A; Fallahi, P; Ferrannini, E; Ferrari, SM; Franceschini, SS; Paolicchi, A; Piaggi, S; Salvi, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, AM | 1 |
| Yin, HY | 1 |
| Chen, A | 1 |
| Liu, YW | 1 |
| Chuang, MC | 1 |
| He, H | 1 |
| Tighe, S | 1 |
| Sheha, H | 1 |
| Liao, SL | 1 |
| Antonelli, A | 3 |
| Ferrari, SM | 3 |
| Fallahi, P | 3 |
| Frascerra, S | 2 |
| Santini, E | 1 |
| Franceschini, SS | 2 |
| Ferrannini, E | 3 |
| Piaggi, S | 1 |
| Paolicchi, A | 1 |
| Salvi, M | 1 |
| Ruffilli, I | 1 |
| Pupilli, C | 1 |
| Bernini, G | 1 |
| Sellari-Franceschini, S | 1 |
| Gelmini, S | 1 |
4 other studies available for pioglitazone and Graves Ophthalmopathy
| Article | Year |
|---|---|
Celecoxib and Pioglitazone as Potential Therapeutics for Regulating TGF-β-Induced Hyaluronan in Dysthyroid Myopathy.
Topics: Adult; Blotting, Western; Case-Control Studies; Celecoxib; Cells, Cultured; Cyclooxygenase 2 Inhibit | 2016 |
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Topics: Adipocytes; Cells, Cultured; Chemokine CXCL11; Chemokine CXCL9; Dose-Response Relationship, Drug; En | 2009 |
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
Topics: Adipocytes; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chemokine CXCL10; Femal | 2011 |
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
Topics: Cells, Cultured; Chemokine CCL2; Chemokine CXCL10; Fenofibrate; Fibroblasts; Graves Ophthalmopathy; | 2012 |